Food naturally boosts your body’s GLP-1 levels, explained Dr. Sun Kim, an endocrinologist at Stanford Health Care in ...

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

For GLP-1 treatment in particular, employers “need to make sure the coverage is married with a patient engagement program, ...

With weight loss injectables like Ozempic and Mounjaro taking the world by storm, the diet industry is seemingly being left ...

Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide ...

During the years when patients got the same anesthetic management regardless of whether they were on a GLP-1 receptor agonist ...

While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...

Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...

There are several types of GLP-1 medications available, each with varying dosing schedules and forms of administration. Some ...

GLP-1 receptor agonists do not affect cardiovascular, kidney, or safety outcomes regardless of SGLT2 inhibitor use in patients with type 2 diabetes.